Cartesian Therapeutics Inc (RNAC)

$10.50 -0.07 (-0.66%)
Market Cap 310.11M
Revenue (ttm) 38.91M
Net Income (ttm) -77.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -198.97%
Debt to Equity Ratio 0.00
Volume 96,200
Avg Vol 101,846
Day's Range N/A - N/A
Shares Out 25.91M
Stochastic %K 39%
Beta 0.55
Analysts Strong Sell
Price Target $38.14

Latest News on RNAC

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 8, 2025, 7:00 AM EDT - 11 days ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics Announces New Employment Inducement Grants

Apr 2, 2025, 7:05 AM EDT - 17 days ago

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 18 days ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grant

Mar 6, 2025, 7:05 AM EST - 6 weeks ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Feb 18, 2025, 7:00 AM EST - 2 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Jan 27, 2025, 7:00 AM EST - 2 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Dec 3, 2024, 6:00 AM EST - 4 months ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 21, 2024, 7:00 AM EST - 5 months ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Cartesian Therapeutics: Uncertainty Remains

Nov 10, 2024, 12:26 PM EST - 5 months ago

Cartesian Therapeutics: Uncertainty Remains

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 17, 2024, 9:45 AM EDT - 7 months ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Sep 3, 2024, 7:00 AM EDT - 8 months ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 4:05 PM EDT - 10 months ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 12:55 PM EDT - 10 months ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:40 AM EDT - 10 months ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 10 months ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:31 AM EDT - 10 months ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Jul 2, 2024, 6:30 AM EDT - 10 months ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 11 months ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

Mar 5, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland